{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:25:03Z","timestamp":1790007903076,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Richard and Edith Strauss Canada Foundation"},{"name":"Fondo de Investigaciones Sanitarias"},{"name":"Redes tem\u00e1ticas de Investigaci\u00f3n Cooperativa en Salud"},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Genetics & Development"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.gde.2017.11.002","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T13:30:51Z","timestamp":1511271051000},"page":"89-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Eukaryotic initiation factor 4F \u2014 sidestepping resistance mechanisms arising from expression heterogeneity"],"prefix":"10.1016","volume":"48","author":[{"given":"Jennifer","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago Ramon y","family":"Cajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahum","family":"Sonenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gde.2017.11.002_sbref0005","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.gde.2017.11.002_bib0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molonc.2010.11.003","article-title":"Deconstructing the molecular portraits of breast cancer","volume":"5","author":"Prat","year":"2011","journal-title":"Mol Oncol"},{"key":"10.1016\/j.gde.2017.11.002_bib0015","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/S0140-6736(11)61539-0","article-title":"Gene expression profiling in breast cancer: classification, prognostication, and prediction","volume":"378","author":"Reis-Filho","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.gde.2017.11.002_bib0020","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/aps.2015.92","article-title":"Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment","volume":"36","author":"Sun","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.gde.2017.11.002_bib0025","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.gde.2017.11.002_bib0030","first-page":"743","article-title":"Selective protein phosphorylation in heterogeneous subpopulations of human colon carcinoma cells","volume":"45","author":"Chakrabarty","year":"1985","journal-title":"Cancer Res"},{"key":"10.1016\/j.gde.2017.11.002_bib0035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0304-3835(85)90037-0","article-title":"Selective nuclear protein phosphorylation\/dephosphorylation in subpopulations of human colonic carcinoma cells","volume":"28","author":"Chakrabarty","year":"1985","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gde.2017.11.002_bib0040","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/379088a0","article-title":"Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours","volume":"379","author":"Graeber","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.gde.2017.11.002_bib0045","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gde.2017.11.002_bib0050","doi-asserted-by":"crossref","first-page":"10206","DOI":"10.18632\/oncotarget.2602","article-title":"Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma","volume":"5","author":"Spagnolo","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.gde.2017.11.002_bib0055","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.gde.2017.11.002_bib0060","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","article-title":"Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate","volume":"103","author":"O\u2019Dwyer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.gde.2017.11.002_sbref0065","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.24594","article-title":"Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma","volume":"92","author":"Yu","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.gde.2017.11.002_sbref0070","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/nm.4165","article-title":"Therapeutic targeting of splicing in cancer","volume":"22","author":"Lee","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.gde.2017.11.002_bib0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd4505","article-title":"Targeting the translation machinery in cancer","volume":"14","author":"Bhat","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.gde.2017.11.002_bib0080","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.cell.2007.07.020","article-title":"Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis","volume":"130","author":"Dai","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.gde.2017.11.002_bib0085","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1158\/0008-5472.CAN-14-2789","article-title":"Targeting the eIF4F translation initiation complex: a critical nexus for cancer development","volume":"75","author":"Pelletier","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.gde.2017.11.002_bib0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/250199a0","article-title":"Three abundance classes in HeLa cell messenger RNA","volume":"250","author":"Bishop","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.gde.2017.11.002_bib0095","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/0092-8674(76)90139-2","article-title":"The expression classes in HeLa cell messenger RNA","volume":"9","author":"Hastie","year":"1976","journal-title":"Cell"},{"key":"10.1016\/j.gde.2017.11.002_sbref0100","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1101\/gr.197566.115","article-title":"nanoCAGE reveals 5\u2032 UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs","volume":"26","author":"Gandin","year":"2016","journal-title":"Genome Res"},{"key":"10.1016\/j.gde.2017.11.002_bib0105","doi-asserted-by":"crossref","first-page":"14134","DOI":"10.1073\/pnas.1005320107","article-title":"eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression","volume":"107","author":"Furic","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.gde.2017.11.002_sbref0110","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/onc.2014.146","article-title":"Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3","volume":"34","author":"Robichaud","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.gde.2017.11.002_bib0115","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1128\/MCB.24.15.6539-6549.2004","article-title":"Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development","volume":"24","author":"Ueda","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.gde.2017.11.002_bib0120","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1158\/0008-5472.CAN-04-2677","article-title":"Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities","volume":"64","author":"Topisirovic","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.gde.2017.11.002_bib0125","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1101\/gad.1604407","article-title":"Dissecting eIF4E action in tumorigenesis","volume":"21","author":"Wendel","year":"2007","journal-title":"Genes Dev"},{"key":"10.1016\/j.gde.2017.11.002_bib0130","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/cam4.817","article-title":"peIF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomas","volume":"5","author":"Martinez-Saez","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.gde.2017.11.002_bib0135","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/jir.2012.0142","article-title":"The oncogene eIF4E: using biochemical insights to target cancer","volume":"33","author":"Carroll","year":"2013","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.gde.2017.11.002_bib0140","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1158\/0008-5472.CAN-07-0881","article-title":"4E-binding protein 1: a key molecular \u201cfunnel factor\u201d in human cancer with clinical implications","volume":"67","author":"Armengol","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.gde.2017.11.002_bib0145","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.humpath.2008.12.019","article-title":"Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis","volume":"40","author":"Castellvi","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.gde.2017.11.002_bib0150","first-page":"1337","article-title":"The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model","volume":"39","author":"Pons","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.gde.2017.11.002_bib0155","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/cncr.22195","article-title":"Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer","volume":"107","author":"Castellvi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.gde.2017.11.002_bib0160","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ijrobp.2009.01.004","article-title":"Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy","volume":"75","author":"Benavente","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.gde.2017.11.002_bib0165","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.juro.2013.06.015","article-title":"mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior","volume":"190","author":"Ferrandiz-Pulido","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.gde.2017.11.002_bib0170","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00428-015-1860-2","article-title":"Phosphorylated 4E-binding protein 1 expression is associated with poor prognosis in small-cell lung cancer","volume":"467","author":"Roh","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.gde.2017.11.002_bib0175","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1158\/1078-0432.CCR-09-0986","article-title":"Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer","volume":"16","author":"Yoshizawa","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gde.2017.11.002_bib0180","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s12094-014-1203-9","article-title":"The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets","volume":"16","author":"Ramon y Cajol","year":"2014","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.gde.2017.11.002_bib0185","first-page":"998","article-title":"mRNA cap-binding protein: cloning of the gene encoding protein synthesis initiation factor eIF-4E from Saccharomyces cerevisiae","volume":"7","author":"Altmann","year":"1987","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.gde.2017.11.002_sbref0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2015.05.049","article-title":"Differential requirements for eIF4E dose in normal development and cancer","volume":"162","author":"Truitt","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.gde.2017.11.002_bib0195","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.celrep.2012.02.010","article-title":"Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis","volume":"1","author":"Lin","year":"2012","journal-title":"Cell Rep"},{"key":"10.1016\/j.gde.2017.11.002_bib0200","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1172\/JCI32044","article-title":"Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity","volume":"117","author":"Graff","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.gde.2017.11.002_sbref0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.07.005","article-title":"Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening","volume":"170","author":"McDonald","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.gde.2017.11.002_bib0210","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1016\/S0021-9258(18)53358-5","article-title":"The p46 subunit of eukaryotic initiation factor (eIF)-4F exchanges with eIF-4A","volume":"268","author":"Yoder-Hill","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.gde.2017.11.002_bib0215","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1261\/rna.033209.112","article-title":"A cellular response linking eIF4AI activity to eIF4AII transcription","volume":"18","author":"Galicia-Vazquez","year":"2012","journal-title":"RNA"},{"key":"10.1016\/j.gde.2017.11.002_bib0220","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1261\/rna.052225.115","article-title":"eIF4AII is dispensable for miRNA-mediated gene silencing","volume":"21","author":"Galicia-Vazquez","year":"2015","journal-title":"RNA"},{"key":"10.1016\/j.gde.2017.11.002_bib0225","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1038\/bcj.2013.25","article-title":"Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A","volume":"3","author":"Cencic","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.gde.2017.11.002_bib0230","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.bbagrm.2014.09.006","article-title":"Targeting the eIF4A RNA helicase as an anti-neoplastic approach","volume":"1849","author":"Chu","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.gde.2017.11.002_bib0235","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature13572","article-title":"eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies","volume":"513","author":"Boussemart","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.gde.2017.11.002_bib0240","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1021\/ol400401d","article-title":"Synthesis of biotinylated episilvestrol: highly selective targeting of the translation factors eIF4AI\/II","volume":"15","author":"Chambers","year":"2013","journal-title":"Org Lett"},{"key":"10.1016\/j.gde.2017.11.002_sbref0245","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1016\/j.celrep.2016.05.005","article-title":"CRISPR-mediated drug-target validation reveals selective pharmacological inhibition of the RNA helicase, eIF4A","volume":"15","author":"Chu","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.gde.2017.11.002_bib0250","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/cb400158t","article-title":"Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex","volume":"8","author":"Sadlish","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.gde.2017.11.002_sbref0255","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature17978","article-title":"Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor","volume":"534","author":"Iwasaki","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.gde.2017.11.002_bib0260","first-page":"2651","article-title":"Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model","volume":"118","author":"Bordeleau","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.gde.2017.11.002_bib0265","doi-asserted-by":"crossref","first-page":"e5223","DOI":"10.1371\/journal.pone.0005223","article-title":"Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol","volume":"4","author":"Cencic","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.gde.2017.11.002_bib0270","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1128\/MCB.23.1.26-37.2003","article-title":"The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation","volume":"23","author":"Yang","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.gde.2017.11.002_bib0275","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature13485","article-title":"RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer","volume":"513","author":"Wolfe","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.gde.2017.11.002_bib0280","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1186\/s13059-014-0476-1","article-title":"Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation","volume":"15","author":"Rubio","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.gde.2017.11.002_bib0285","doi-asserted-by":"crossref","first-page":"13984","DOI":"10.1073\/pnas.1008136107","article-title":"Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development","volume":"107","author":"Ueda","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.gde.2017.11.002_bib0290","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1074\/jbc.M103607200","article-title":"Phosphorylation of eukaryotic initiation factor 4E markedly reduces its affinity for capped mRNA","volume":"277","author":"Scheper","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.gde.2017.11.002_bib0295","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/emboj\/16.8.1909","article-title":"Mitogen-activated protein kinases activate the serine\/threonine kinases Mnk1 and Mnk2","volume":"16","author":"Waskiewicz","year":"1997","journal-title":"Embo J"},{"key":"10.1016\/j.gde.2017.11.002_bib0300","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1128\/MCB.21.16.5500-5511.2001","article-title":"Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2","volume":"21","author":"Knauf","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.gde.2017.11.002_bib0305","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1158\/0008-5472.CAN-10-3298","article-title":"Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases","volume":"71","author":"Konicek","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.gde.2017.11.002_bib0310","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1182\/blood-2013-01-477216","article-title":"Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors","volume":"121","author":"Altman","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.gde.2017.11.002_bib0315","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/leu.2015.180","article-title":"Discovery of a BTK\/MNK dual inhibitor for lymphoma and leukemia","volume":"30","author":"Wu","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.gde.2017.11.002_bib0320","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/cmdc.201300231","article-title":"Rational design of resorcylic acid lactone analogues as covalent MNK1\/2 kinase inhibitors by tuning the reactivity of an enamide Michael acceptor","volume":"8","author":"Xu","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.gde.2017.11.002_bib0325","doi-asserted-by":"crossref","first-page":"530","DOI":"10.18632\/oncotarget.1528","article-title":"First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines","volume":"5","author":"Ramalingam","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.gde.2017.11.002_bib0330","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1021\/jm501792c","volume":"58","author":"Mbatia","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.gde.2017.11.002_bib0335","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.18632\/oncotarget.3084","article-title":"Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines","volume":"6","author":"Ramamurthy","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.gde.2017.11.002_bib0340","series-title":"57th Annual ASH Meeting, Orlando, FL","author":"Webster","year":"2015"}],"container-title":["Current Opinion in Genetics & Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959437X17301156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959437X17301156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T11:54:33Z","timestamp":1760702073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959437X17301156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":68,"alternative-id":["S0959437X17301156"],"URL":"https:\/\/doi.org\/10.1016\/j.gde.2017.11.002","relation":{},"ISSN":["0959-437X"],"issn-type":[{"value":"0959-437X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eukaryotic initiation factor 4F\u2014sidestepping resistance mechanisms arising from expression heterogeneity","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Genetics & Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gde.2017.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}